NASDAQ:THRX Theseus Pharmaceuticals (THRX) Stock Price, News & Analysis → The AI Defense Stock Set to Soar (From Behind the Markets) (Ad) Free THRX Stock Alerts $4.06 0.00 (0.00%) (As of 02/14/2024) Add Compare Share Share Today's Range$4.06▼$4.0650-Day Range$3.99▼$4.0852-Week Range$2.05▼$12.37VolumeN/AAverage Volume592,167 shsMarket Capitalization$179.57 millionP/E RatioN/ADividend YieldN/APrice Target$6.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Theseus Pharmaceuticals alerts: Email Address Ad Huge AlertsTrending Stocks Sent To You In Real Time Sign up today and get instant access to our next stock alert! You do not want to miss out on this next pick! Our stock picks have been known to soar! Click To Get Our Next Alert About Theseus Pharmaceuticals Stock (NASDAQ:THRX)Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors. The company also develops THE-349, a fourth-generation selective epidermal growth factor receptor inhibitor to address C797X-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer. Its development programs address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. The company was incorporated in 2017 and is based in Cambridge, Massachusetts. As of February 14, 2024, Theseus Pharmaceuticals, Inc. operates as a subsidiary of Concentra Biosciences, LLC.Read More THRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart THRX Stock News HeadlinesFebruary 14, 2024 | finance.yahoo.comTheseus Pharmaceuticals Announces Closing of Tender OfferFebruary 14, 2024 | prnewswire.comTheseus Pharmaceuticals Announces Closing of Tender OfferMarch 28, 2024 | DTI (Ad)the most reliable asset on earth is making a comebackGlobal tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.January 30, 2024 | finance.yahoo.comConcentra Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Theseus PharmaceuticalsJanuary 20, 2024 | stockhouse.comSHAREHOLDER NOTICE: Halper Sadeh LLC Investigates CSTR, THRX, GRCL, ROVRDecember 31, 2023 | businesswire.comTHESEUS PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of ...December 29, 2023 | finance.yahoo.comIs Theseus Pharmaceuticals (THRX) Stock a Solid Choice Right Now?December 27, 2023 | markets.businessinsider.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DSKE, KRTX, THRX, CONNMarch 28, 2024 | Crypto 101 Media (Ad)Major Elon Musk Crypto Leak RevealedReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.December 22, 2023 | marketwatch.comTheseus Pharmaceuticals Shares Rise 9.3% on Deal to Be Acquired by ConcentraDecember 22, 2023 | marketwatch.comConcentra Biosciences to Acquire Theseus Pharmaceuticals for $3.90 to $4.05/ShrDecember 22, 2023 | markets.businessinsider.comTheseus Pharma To Acquire Concentra Biosciences For $4.05/Shr In CashDecember 22, 2023 | tmcnet.comTHRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Theseus Pharmaceuticals, Inc. Is Fair to ShareholdersDecember 22, 2023 | finance.yahoo.comTheseus Pharmaceuticals Enters into Agreement to Be Acquired by Concentra Biosciences for between $3.90 and $4.05 in Cash per Share Plus a Contingent Value RightNovember 27, 2023 | msn.comUP Fintech, Cerence, Irsa Inversiones Y Representaciones among premarket gainers packNovember 27, 2023 | markets.businessinsider.comTheseus Pharma To Evaluate Expression Of Interest From Foresite, OrbiM And Proposal From ConcentraNovember 27, 2023 | finance.yahoo.comTheseus Pharmaceuticals Confirms Receipt of Unsolicited Expression of Interest from Foresite Capital, LLC and OrbiMed Advisors LLC and Unsolicited Proposal from Concentra Biosciences LLCNovember 14, 2023 | finance.yahoo.comTheseus Pharmaceuticals Inc (THRX) Explores Strategic Alternatives Amidst Workforce ReductionNovember 14, 2023 | bizjournals.comTwo years after IPO, Theseus Pharmaceuticals lays off most its staff, explores saleNovember 14, 2023 | benzinga.comThinking about buying stock in Theseus Pharmaceuticals, Vuzix, Jaguar Global Growth, Fisker, or Cardio Diagnostics Holdings?November 13, 2023 | marketwatch.comTheseus Pharmaceuticals Shares Rise 35% on Workforce Reduction, Strategic Alternatives ConsiderationNovember 13, 2023 | msn.comTheseus Pharmaceuticals explores strategic options; cuts workforce by 72%November 13, 2023 | finance.yahoo.comTheseus Pharmaceuticals Announces Process to Explore Strategic AlternativesNovember 7, 2023 | morningstar.comTheseus Pharmaceuticals Inc THRXNovember 7, 2023 | finance.yahoo.comTheseus Pharmaceuticals to Participate in the Stifel 2023 Healthcare ConferenceOctober 9, 2023 | finance.yahoo.comTheseus Pharmaceuticals (NASDAQ:THRX) Is In A Good Position To Deliver On Growth PlansSeptember 29, 2023 | msn.comTheseus Pharmaceuticals: Picking Up The Pieces After A Lead FailureSee More Headlines Receive THRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Theseus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/15/2021Today3/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:THRX CUSIPN/A CIK1745020 Webtheseusrx.com Phone857-400-9491FaxN/AEmployees38Year FoundedN/APrice Target and Rating Average Stock Price Target$6.75 High Stock Price Target$9.00 Low Stock Price Target$4.00 Potential Upside/Downside+66.3%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-50,610,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-24.84% Return on Assets-23.64% Debt Debt-to-Equity RatioN/A Current Ratio29.93 Quick Ratio29.93 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.36 per share Price / Book0.76Miscellaneous Outstanding Shares44,230,000Free Float23,575,000Market Cap$179.57 million OptionableOptionable Beta3.98 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesDr. Iain D. Dukes DPHIL (Age 66)M.A., Co-Founder & Chairman Comp: $67.28kMr. Bradford D. Dahms (Age 36)President, CFO & Director Comp: $480.95kMs. Kristine Callahan CPAVP & ControllerKey CompetitorsGlycoMimeticsNASDAQ:GLYCTelomir PharmaceuticalsNASDAQ:TELOMediWoundNASDAQ:MDWDClearside BiomedicalNASDAQ:CLSDKinnate BiopharmaNASDAQ:KNTEView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 6,429 shares on 3/11/2024Ownership: 1.799%Goldman Sachs Group Inc.Bought 16,982 shares on 3/1/2024Ownership: 0.038%Virtu Financial LLCBought 26,467 shares on 2/26/2024Ownership: 0.060%Vanguard Group Inc.Bought 6,429 shares on 2/15/2024Ownership: 1.799%Citadel Advisors LLCBought 14,100 shares on 2/15/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions THRX Stock Analysis - Frequently Asked Questions Should I buy or sell Theseus Pharmaceuticals stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Theseus Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" THRX shares. View THRX analyst ratings or view top-rated stocks. What is Theseus Pharmaceuticals' stock price target for 2024? 4 brokers have issued 12-month price targets for Theseus Pharmaceuticals' shares. Their THRX share price targets range from $4.00 to $9.00. On average, they expect the company's share price to reach $6.75 in the next twelve months. This suggests a possible upside of 66.3% from the stock's current price. View analysts price targets for THRX or view top-rated stocks among Wall Street analysts. How have THRX shares performed in 2024? Theseus Pharmaceuticals' stock was trading at $4.05 at the beginning of 2024. Since then, THRX shares have increased by 0.2% and is now trading at $4.06. View the best growth stocks for 2024 here. How were Theseus Pharmaceuticals' earnings last quarter? Theseus Pharmaceuticals, Inc. (NASDAQ:THRX) announced its quarterly earnings data on Monday, November, 15th. The company reported ($5.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by $4.93. When did Theseus Pharmaceuticals IPO? Theseus Pharmaceuticals (THRX) raised $150 million in an IPO on Thursday, October 7th 2021. The company issued 10,000,200 shares at a price of $14.00-$16.00 per share. Who are Theseus Pharmaceuticals' major shareholders? Theseus Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Frazier Life Sciences Management L.P. (4.79%), BML Capital Management LLC (2.51%), BML Capital Management LLC (2.51%), Vanguard Group Inc. (1.80%), Vanguard Group Inc. (1.80%) and Highbridge Capital Management LLC (1.39%). Insiders that own company stock include Bradford D Dahms, Carl L Gordon, Foresite Capital Management V, and Timothy P Clackson. View institutional ownership trends. How do I buy shares of Theseus Pharmaceuticals? Shares of THRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:THRX) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryUrgent: Protect Your Investments from a Chinese InvasionBehind the MarketsSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Theseus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.